Roche has cut 20% of new molecular entities from its pipeline since the third quarter of last year as it overhauls its portfolio to focus on “high-impact” projects. CEO Thomas Schinecker noted Wednesday alongside the company’s first quarter financial results that the terminated assets, which include three cancer drugs, were not innovative enough.
The executive indicated that the gaps in its pipeline will be filled with external drugs. “We are open for M&A,” Schinecker said, with a focus on areas including cardiovascular and metabolism disorders, neuroscience and oncology. “Based on whether or not the deal makes sense, then we are also open to doing larger acquisitions,” he added.
Roche’s first-quarter revenue slipped 6% to CHF 14.4 billion ($), with sales of prescription drugs falling by the same percentage to CHF 10.9 billion. Schinecker explained that “the appreciation of the Swiss franc versus most currencies impacted sales,” which would have risen by 2% on a constant exchange rate (CER) basis.
The company reaffirmed that revenue and core earnings per share will both increase in the mid-single-digit range on a CER basis. Roche noted that for the remainder of the year, “there will be no further material impact of COVID-19 sales decline.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.